Antigen-binding molecule comprising altered antibody variable region
AU2026207952A1Pending Publication Date: 2026-08-13CHUGAI PHARMA CO LTD
View PDF 0 Cites 0 Cited by
Patent Information
- Authority / Receiving Office
- AU · AU
- Patent Type
- Applications
- Current Assignee / Owner
- Filing Date
- 2026-07-21
- Publication Date
- 2026-08-13
Smart Images

Figure 00000190_0000 
Figure 00000251_0000 
Figure 00000252_0000
Abstract
[ABSTRACT] An antigen-binding molecule capable of binding to multiple different antigens (e.g., CD3 on T cells, and CD137 on T cells, NK cells, DC cells, and / or the like), but does not nonspecifically crosslink two or more immune cells such as T cells is provided. Such multispecific antigen- binding molecule is capable of modulating and / or activating an immune response while circumventing the cross-linking between different cells (e.g., different T cells) resulting from the binding of a conventional multispecific antigen-binding molecule to antigens expressed on the different cells, which is considered to be responsible for adverse reactions when the multispecific antigen-binding molecule is used as a drug. 20 26 20 79 52 21 J ul 2 02 6 2 0 2 6 2 0 7 9 5 2 2 1 J u l 2 0 2 6
Need to check novelty before this filing date? Find Prior Art